Risk adapted high-dose and dose-dense therapies modulate the impact of biological classification in diffuse large B-cell lymphoma prognosis

Diffuse large B-cell lymphoma (DLBCL) is a highly heterogeneous disease entity.[1][1] Young patients with high-intermediate and high aa-IPI score seem to be good candidates to receive alternative treatments to standard RCHOP-21 including EPOCH-R,[2][2] R-ACVBP+HDT-ASCT[3][3] and upfront autologous